Eli Lilly (NY:LLY)

Pfizer’s BRAFTOVI BREAKWATER Trial Delivers Landmark Survival Gains in Colorectal Cancer

Topics Economy Intellectual Property

Today 10:33 EST

NEW YORK — Pfizer Inc. (NYSE: PFE) has announced breakthrough results from its Phase 3 BREAKWATER clinical trial, demonstrating that its BRAFTOVI (encorafenib) regimen significantly improves both...

Forget Ozempic: This Obesity‑Drug Giant Is Grabbing the Biggest Slice of the GLP‑1 Gold Rush ↗

Today 7:30 EST

Ozempic's rival is generating blockbuster revenue and gaining market share.

Nasdaq, S&P 500 Futures Edge Higher, Trump Speech In Focus: Why WMT, META, IBRX, MSFT, EBAY Are On Traders' Radar Today ↗

Eli Lilly & Co (NYSE:LLY) Combines Explosive Growth with a Bullish Technical Setup ↗

February 17, 2026

Via Chartmill

Today 4:18 EST

Data from Stocktwits indicated retail sentiment towards SPY and QQQ cooled to neutral.

Expensive stocks typically earn their valuations through superior growth rates that other companies simply can’t match. The flip side though is that these lofty expectations make them particularly...

Topics ETFs Economy Government

2 High-Flying Stocks on Our Buy List and 1 Facing Challenges

February 18, 2026

Via StockStory

Topics Firearms

Here's How Much You Would Have Made Owning Eli Lilly Stock In The Last 15 Years ↗

February 18, 2026

Via Benzinga

Eli Lilly's Landmark Trial Shows Major Psoriasis-Obesity Breakthrough With Taltz-Zepbound Combo ↗

February 18, 2026

Eli Lilly's latest trial results and new licensing agreement show promise in treating psoriasis, obesity, and kidney disease.

Via Benzinga

Health Care Sector (XLV) Shows Resilience Amid Tech Volatility and Strong Jobs Data

February 18, 2026

As the broader market grappled with a violent valuation reset in the technology sector, the health care industry emerged as a critical anchor for investors in early 2026. The Health Care Select Sector...

The Trillion-Dollar Pharmaceutical Giant: Eli Lilly Makes History as Weight-Loss Revolution Drives Unprecedented Growth

Topics Artificial Intelligence ETFs Earnings

February 17, 2026

In a historic moment for the global healthcare industry, Eli Lilly and Company (NYSE:LLY) has officially cemented its position as the world’s first pharmaceutical company to surpass a $1 trillion...

Should You Buy the Vanguard S&P 500 ETF With the Stock Market Near a Record High? History Offers a Clear Answer ↗

Topics Earnings Economy

February 17, 2026

Despite recent volatility, trends like artificial intelligence could fuel another strong year for the stock market.

Agios Stock Down 16% in a Year as Fund Cuts Stake by $5.6 Million After 50% November Crash ↗

Topics Artificial Intelligence ETFs Stocks

February 17, 2026

Agios Pharmaceuticals targets rare blood disorders with a marketed anemia drug and a focused clinical-stage pipeline.

Cogent Biosciences Stock Soars 346% in a Year, but One Fund Just Sold Off $4.5 Million ↗

Topics Regulatory Compliance

February 17, 2026

This biotech firm develops precision therapies targeting rare genetic diseases, with a lead candidate focused on oncology indications.

Structure Therapeutics develops oral therapies for chronic diseases, using a proprietary platform to target G-protein-coupled receptors.

Topics Regulatory Compliance

Structure Therapeutics Stock Up 187% in One Year as Fund Trims $8 Million From Stake ↗

February 17, 2026

Kymera Therapeutics develops targeted protein degradation therapies for immunology and oncology, advancing multiple clinical-stage programs.

Kymera Therapeutics Stock Up 120% in 1 Year as Fund Adds $3 Million More ↗

February 17, 2026

A robust pipeline is essential for a buy-and-hold pharmaceutical stock.

1 Reason I'd Buy Eli Lilly Stock and Never Sell ↗

February 17, 2026

As of February 17, 2026, the biotechnology sector is undergoing its most significant structural transformation in decades, a period now widely termed the "Biotechnology Renaissance." Following a...

Topics Intellectual Property

The Biotechnology Renaissance: AI and Capital Collide in a Multi-Trillion Dollar Pivot

February 17, 2026

NVO Stock Generates Retail Buzz After European Commission Approves 7.2 MG Once-Weekly Dose Of Wegovy Injection ↗

Topics Artificial Intelligence Economy Initial Public Offering

February 17, 2026

The approval follows a positive recommendation from the European Medicines Agency and is supported by data from clinical trials involving more than 1,400 participants.

Novo Nordisk and the FDA are both mounting pressure on Hims & Hers Health and other GLP-1 compounders.

Topics Lawsuit

Hims & Hers Faces New Hurdle In Weight-Loss Brawl With Novo Nordisk ↗

February 17, 2026

Via Investor's Business Daily

Topics Lawsuit

2026 Could Be a Big Year for Viking Therapeutics. Time to Buy? ↗

February 17, 2026

Viking should have plenty of news to share with investors this year.

Eli Lilly's Experimental Cancer Drug Cuts Recurrence Risk In Early-Stage Lung Cancer Patients ↗

February 17, 2026

Eli Lilly's lung cancer trial shows lower recurrence risk and strong survival benefit in early-stage patients.

Via Benzinga

Nasdaq, S&P 500 Futures Lower As AI Disruption Fears Linger: Why AAPL, ZIM, OCUL, NCLH Are On Traders' Radar Today ↗

February 17, 2026

Wall Street resumed trade after the Presidents’ Day break to find a market still grappling with the ‘AI disruption’ trade.

Novo Nordisk's plan to gain ground in the GLP-1 space is slowly taking shape.

Topics Artificial Intelligence ETFs Economy

Novo Nordisk's New Diabetes Drug Outshines Ozempic: Is The Stock a Buy? ↗

February 16, 2026

Lamb Weston is a global leader in frozen potato products, serving both retail and foodservice markets with a diversified brand portfolio.

Liberty One Cuts Its Lamb Weston Position in Half With $32 Million Sale ↗

February 16, 2026

And there's more than one way to monetize this technology.

Topics Economy Regulatory Compliance Supply Chain

Forget AI Stocks: This Pharma Giant Is Using AI to Dominate Drug Discovery ↗

February 15, 2026

The Smartest Growth ETF to Buy With $1,000 Right Now. (Hint: It Has Averaged Annual Gains of 18.6% Over the Past 10 Years.) ↗

Topics Artificial Intelligence

February 15, 2026

It's an easy way to quickly own 150-plus companies growing at a solid clip.

Eli Lilly Just Delivered Great News for Investors -- and It Goes Beyond Weight-Loss Drugs ↗

Topics ETFs

February 15, 2026

Eli Lilly isn't a one-trick pony.

Eli Lilly continues to pursue smart acquisitions for the long term.

What Is One of the Best Pharmaceutical Stocks to Own for the Next 10 Years? ↗

February 14, 2026

Topics Intellectual Property

Got $500? 2 Pharma Stocks to Buy and Hold Forever. ↗

February 14, 2026

Growth, value, or both?

Novo Nordisk To Meet Wegovy Pill Demand In US Before Expanding To Avoid Supply Shortage, Says CEO Doustdar ↗

February 13, 2026

Novo is looking to ensure the U.S. market is supplied before choosing another country to scale in, Doustdar said in an interview with CNBC.